IDEAYA Biosciences, Inc. (IDYA) has entered into a clinical study collaboration and supply agreement with Gilead Sciences, Inc. to evaluate the efficacy and safety of IDE397, its investigational small molecule MAT2A inhibitor, in combination with Gilead's Trodelvy, a Trop-2 directed antibody-drug conjugate, in a Phase 1 trial for treatment of MTAP-Deletion Bladder Cancer.
IDEAYA Biosciences, Inc. (IDYA) announced selection of a Werner Helicase Inhibitor Development Candidate, a potent, selective, small molecule inhibitor of the helicase domain of Werner protein.
Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
IDEAYA Biosciences, Inc. (IDYA) announced the FDA has completed its review of the Amgen-sponsored Investigational New Drug application and concluded that the proposed clinical study may proceed to evaluate IDE397 in combination with AMG 193 in solid tumors having MTAP deletion.
NEW YORK CITY (dpa-AFX) - IDEAYA Biosciences, Inc. (IDYA) has amended its clinical trial collaboration and supply agreements with Pfizer Inc. (PFE) to support evaluation of darovasertib and crizotinib